Latest Trials

EudraCT Number: 2022-003865-39 Sponsor Protocol Number: WSG-AM12 Start Date: 2023-05-04
Sponsor Name: Westdeutsche Studiengruppe GmbH
Full Title: NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer
Medical condition: HER2+ early breast cancer
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-003951-41 Sponsor Protocol Number: BFS-AS-40184 Start Date: 2023-05-04
Sponsor Name: Teva Branded Pharmaceutical Products R&D, Inc.
Full Title: CONNected Electronic Inhalers Asthma Control Trial 3 (“CONNECT 3”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus th...
Medical condition: Asthma
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2023-000033-33 Sponsor Protocol Number: 83631 Start Date: 2023-05-03
Sponsor Name: Maastricht University
Full Title: Short-term safety and efficacy of ketohexokinase inhibition in patients with hereditary fructose intolerance.
Medical condition: Hereditary fructose intolerance
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10019878 Hereditary fructose intolerance PT
20.1 10010331 - Congenital, familial and genetic disorders 10017397 Fructose intolerance hereditary LLT
21.0 10027433 - Metabolism and nutrition disorders 10072104 Fructose intolerance PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003056-14 Sponsor Protocol Number: VTX958-203 Start Date: 2023-05-03
Sponsor Name: Ventyx Biosciences, Inc
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients with Active Psoriatic Arthritis
Medical condition: Active Psoriatic Arthritis
Disease: Version SOC Term Classification Code Term Level
21.0 100000004859 10037160 Psoriatic arthritis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) HU (Prematurely Ended) BG (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003452-14 Sponsor Protocol Number: SBC007C401 Start Date: 2023-05-02
Sponsor Name: Berlin Cures GmbH
Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability...
Medical condition: long Covid
Disease: Version SOC Term Classification Code Term Level
25.1 10021881 - Infections and infestations 10087832 COVID-19 rebound LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) FI (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005551-36 Sponsor Protocol Number: NL79416.018.21 Start Date: 2023-05-01
Sponsor Name: Amsterdam University Medical Center, AMC
Full Title: Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction: A Multicenter Randomized...
Medical condition: Myocardial infarction related cardiogenic shock
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003866-19 Sponsor Protocol Number: 83336 Start Date: 2023-05-01
Sponsor Name: Amsterdam UMC location AMC
Full Title: The effect of low-dose rhythmic 17-β-estradiol administration on bone turnover in postmenopausal women
Medical condition: Osteoporosis prevention
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000365-41 Sponsor Protocol Number: CNTO1959UCO3004 Start Date: 2023-04-26
Sponsor Name: Janssen-Cilag International NV
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Mode...
Medical condition: Moderately to Severely Active Ulcerative Colitis
Disease: Version SOC Term Classification Code Term Level
20.1 100000004856 10045365 Ulcerative colitis LLT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing) CZ (Ongoing) HU (Ongoing) BG (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-001793-36 Sponsor Protocol Number: GTX-102-001 Start Date: 2023-04-26
Sponsor Name: Ultragenyx Pharmaceutical Inc.
Full Title: A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)
Medical condition: Angelman Syndrome
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) FR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005099-21 Sponsor Protocol Number: MER-XMT-1536-3 Start Date: 2023-04-25
Sponsor Name: Mersana Therapeutics, Inc.
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensiti...
Medical condition: Recurrent, Platinum-Sensitive Ovarian Cancer
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: FR (Ongoing) NO (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) IT (Ongoing) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) NL (Completed)
Trial results: (No results available)

Sponsors and Collaborators

Medical Conditions

Drug Interventions